CLARET ASSET MANAGEMENT Corp grew its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 12.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,161 shares of the biopharmaceutical company’s stock after purchasing an additional 2,128 shares during the period. CLARET ASSET MANAGEMENT Corp’s holdings in Bristol-Myers Squibb were worth $972,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Hammer Asset Management LLC increased its holdings in Bristol-Myers Squibb by 9.5% during the first quarter. Hammer Asset Management LLC now owns 40,698 shares of the biopharmaceutical company’s stock worth $1,942,000 after buying an additional 3,525 shares during the last quarter. Perella Weinberg Partners Capital Management LP increased its holdings in Bristol-Myers Squibb by 10.9% during the first quarter. Perella Weinberg Partners Capital Management LP now owns 19,431 shares of the biopharmaceutical company’s stock worth $99,000 after buying an additional 1,905 shares during the last quarter. REDW Wealth LLC acquired a new position in Bristol-Myers Squibb during the first quarter worth $224,000. Kahn Brothers Group Inc. DE increased its holdings in Bristol-Myers Squibb by 2,428.1% during the first quarter. Kahn Brothers Group Inc. DE now owns 504,350 shares of the biopharmaceutical company’s stock worth $24,063,000 after buying an additional 484,400 shares during the last quarter. Finally, Towerview LLC acquired a new position in Bristol-Myers Squibb during the first quarter worth $477,000. Institutional investors own 80.17% of the company’s stock.
A number of equities analysts recently weighed in on BMY shares. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Monday. Atlantic Securities upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price on the stock in a report on Wednesday, August 14th. UBS Group lowered their target price on shares of Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating on the stock in a report on Thursday, June 13th. TheStreet upgraded shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday, September 18th. Finally, Bank of America boosted their target price on shares of Bristol-Myers Squibb from $49.00 to $50.00 and gave the stock a “neutral” rating in a report on Thursday. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Buy” and an average price target of $55.81.
BMY stock traded up $0.98 during midday trading on Friday, reaching $51.76. 6,796,440 shares of the company were exchanged, compared to its average volume of 9,791,409. The company has a debt-to-equity ratio of 1.51, a current ratio of 3.88 and a quick ratio of 3.75. The business has a 50-day moving average price of $49.24 and a two-hundred day moving average price of $47.03. Bristol-Myers Squibb Co has a one year low of $42.48 and a one year high of $60.77. The firm has a market capitalization of $82.38 billion, a price-to-earnings ratio of 13.01, a price-to-earnings-growth ratio of 2.48 and a beta of 0.72.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, topping the Zacks’ consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The firm had revenue of $6.27 billion during the quarter, compared to analysts’ expectations of $6.10 billion. During the same period in the previous year, the business posted $1.01 earnings per share. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. As a group, analysts anticipate that Bristol-Myers Squibb Co will post 4.29 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be given a $0.41 dividend. The ex-dividend date of this dividend is Thursday, October 3rd. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.17%. Bristol-Myers Squibb’s payout ratio is presently 41.21%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Further Reading: Diversification
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.